Mylan N.V. (NASDAQ, TASE: MYL) today announced that its abbreviated new drug application (ANDA) for fluticasone propionate 100, 250, 500 mcg and salmeterol 50 mcg inhalation powder has been accepted ...
LONDON (Reuters) - GlaxoSmithKline's new CEO Emma Walmsley, who takes over on April 1, has won a short-term reprieve from the threat of generic Advair with a delay in U.S. approval for Mylan's copy of ...
1. Wixela Inhub is Mylan’s generic version of Advair, an asthma treatment made by GlaxoSmithKline. 2. Tosymra is a sumatriptan nasal spray used to treat migraines in adults. 3. Imbruvica in ...
LONDON, June 10 (Reuters) - Generic companies hoping to market a cheap copy of GlaxoSmithKline's best-selling inhaled lung drug Advair might have wait until 2012 before winning a green light from ...
Mylan N.V. (NASDAQ:MYL) submits its Abbreviated New Drug Application (ANDA) to the FDA seeking clearance for a generic version of GlaxoSmithKline's (NYSE:GSK) COPD product Advair Diskus (fluticasone ...
Corticosteroid + long-acting beta-2 agonist (LABA). Allow approx. 12hrs between doses. Asthma: ≥12yrs: initially 1 inh of 100/50 or 250/50 or 500/50 twice daily, based on disease severity and previous ...
Fluticasone propionate, salmeterol (as xinafoate); 45mcg/21mcg, 115mcg/21mcg, 230mcg/21mcg; per inh; metered-dose inhaler; CFC-free. Store at room temperature between 68° F and 77° F (20° C and 25° C) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback